Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

The risk of recurrence of hormone-receptor–positive early breast cancer continues indefinitely. Long-term reduction in the risk of recurrence has been achieved with the antiestrogen agent tamoxifen, aromatase inhibitors, or a combination of the two. These treatments are administered in a variety…

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1stHtPl
via IFTTT